COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma
Future Oncology · 2023
DOI: 10.2217/fon-2023-0414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Alexander Cj van Akkooi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, the University of Sydney & Royal Prince Alfred Hospital, 40 Rocklands Road Wollstonecraft, Sydney 2065, NSW, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen and Merck-Pfizer.
Abstract (Originalsprache)
Stage IIB/IIC melanoma has a high risk of recurrence after surgical resection. While, for decades, surgery was the only option for high-risk stage II disease in most countries, adjuvant therapies now exist. Anti-programmed cell death protein 1 (PD-1) antibodies significantly improve recurrence-free survival versus placebo in patients with fully resected stage IIB/IIC melanoma. Combined BRAF MEK inhibitor therapy showed benefits in high-risk stage III and advanced disease; however, its role in patients with fully resected stage BRAF-mutated IIB/IIC melanoma is still unknown. Here we describe the rationale and design of the ongoing randomized, placebo-controlled COLUMBUS-AD trial, the first study of a BRAF-MEK inhibitor combination therapy (encorafenib + binimetinib) in patients with BRAF V600-mutated stage IIB/IIC melanoma. Melanoma is a type of skin cancer. Although most stage II melanomas (cancer affecting the first two layers of skin) can be cured with surgery, the risk of the cancer returning and spreading to other areas of the body is high in some patients with stage IIB/IIC melanoma. Furthermore, once the melanoma has spread, it is much more difficult to treat successfully and remove all the cancer cells from the body. Some melanomas have a DNA alteration (or mutation) in what is known as the BRAF gene. This mutation can be identified by testing a sample of the tumor tissue removed during a biopsy or surgery. Testing for BRAF mutations at diagnosis can help ensure that patients receive the most appropriate treatment for their cancer. In some countries, surgery is the only option for patients with stage II melanoma, while in other countries, patients may be offered additional (adjuvant) anticancer treatment with immunotherapy (agents that work with the immune system to kill cancer cells). While immunotherapy can reduce the risk of melanoma recurrence, persistent, long-term toxicities are common and the use of this treatment in all stage IIB/IIC melanoma patients is not always possible. Here, we describe the rationale and design of an ongoing clinical trial (COLUMBUS-AD), which will be the first study (to our knowledge) to investigate the efficacy and safety of a treatment that specifically targets cancers with BRAF mutations (i.e., the BRAF-MEK inhibitor combination of the drugs encorafenib and binimetinib) in patients with BRAF-mutated stage IIB/IIC melanoma. Clinical Trial Registration: NCT05270044 (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Melanoma Institute Australia, the University of Sydney & Royal Prince Alfred Hospital, 40 Rocklands Road Wollstonecraft, Sydney 2065, NSW, Australia.
- Department of Dermatology, University Hospital (UKSH), Arnold-Heller-Straße 3, 24105, Kiel, Germany.
- Melanoma Institute Australia, University of Sydney, & Mater & Royal North Shore Hospitals, 40 Rocklands Road Wollstonecraft, Sydney 2065, NSW, Australia.
- University of Perugia, Ospedale Santa Maria della Misericordia, Piazzale Giorgio Menghini, 3, 06129, Perugia, Italy.
- EORTC Headquarters, Avenue Emmanuel Mounier 83/11, 1200, Brussels, Belgium.
- Pierre Fabre, Medical & Patient/Consumer Division, 33 avenue Emile Zola, 92100, Boulogne-Billancourt, France.
ORCID-Profile: Alexander Cj van Akkooi, Axel Hauschild, Georgina V Long, Mario Mandala, Michal Kicinski, Paul C Lorigan, Alexander Mm Eggermont
Förderung
- Amgen and Merck-Pfizer
Zitieren
APA
van Akkooi, A. C., Hauschild, A., Long, G. V., Mandala, M., Kicinski, M., Govaerts, A. S., Klauck, I., Ouali, M., Lorigan, P. C., & Eggermont, A. M. (2023). COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma. Future Oncology. https://doi.org/10.2217/fon-2023-0414
Vancouver
van Akkooi AC, Hauschild A, Long GV, Mandala M, Kicinski M, Govaerts AS, et al. COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma. Future Oncology. 2023. doi:10.2217/fon-2023-0414
BibTeX
@article{vanAkkooi2023,
author = {van Akkooi, Alexander Cj and Hauschild, Axel and Long, Georgina V and Mandala, Mario and Kicinski, Michal and Govaerts, Anne-Sophie and Klauck, Isabelle and Ouali, Monia and Lorigan, Paul C and Eggermont, Alexander Mm},
title = {COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2023-0414}
}
EUVIMED